With Apligraf, clinicians have a bioengineered living cell-based treatment for wounds that fail to adequately respond to conventional therapy. Recent findings highlighting the significant burden of these debilitating chronic wounds underscore the urgent need for improved identification, prevention and aggressive treatment. ,
Diabetes affects about 1 million veterans within the VA health care system, which is nearly 20% of the patients the Department sees each year (compared to 8% of the total U.S. population)., Diabetes is also the leading cause of blindness, end-stage renal disease, and amputation for VA patients.  A recent retrospective study found that VA patients with a new diagnosis of a diabetic foot ulcer had significantly higher amputation rates compared to patients treated in adjacent private and public hospitals (6.8% private, 12% public and 23.5% VA, p< 0.001). 
Apligraf contains two layers of human living cells: a layer of differentiated keratinocytes and a layer of fibroblasts in a collagen matrix. When placed on a wound previously unresponsive to treatment, Apligraf provides cells, collagen matrix, and other proteins, and has been demonstrated to promote healing. In controlled clinical studies, Apligraf has been shown to be an effective and safe wound care treatment, superior to conventional treatments alone. Clinical studies of Apligraf application were based on up to 5 treatments, comprising weekly assessments and/or applications, over a 12-week period. Over 650,000 Apligraf units have been shipped for patient application. The product is covered by Medicare, Medicaid and more than 1,500 private insurers.
About Organogenesis Inc.
Having pioneered the field, Massachusetts-based Organogenesis Inc. is a world leading regenerative medicine compa
|SOURCE Organogenesis Inc.|
Copyright©2014 PR Newswire.
All rights reserved